Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 28Head & Neck 14Gastrointestinal 13CNS 13Genitourinary 10Breast 9Endocrine 7Tumor-Agnostic 6Sarcoma 5Other solid neoplasm 3Gynecologic 3Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × vandetanib × Plasma cell × Clear all
NCT00047788 2016-08-24

Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer

Sanofi

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡